Progress in the development of protein biomarkers of oesophageal and XXXX .

@entity1 @entity1442 @entity1820 @entity356
UNASSIGNED: Upper @entity1820 originating in the oesophagus and stomach often present late and have a very poor prognosis. Treatment options include surgery for localised disease but, increasingly, neoadjuvant chemotherapy and radiotherapy is being employed to improve outcome. There is often a variable response to neoadjuvant treatment between individual @entity1 and side effects are relatively common. There is an urgent need for novel biomarkers of upper @entity1820 , not only to improve screening and early diagnosis of the oesophageal and @entity356 when treatment options are potentially more effective, but also to accurately guide therapy in more @entity1442 . The development of predictive biomarkers will also help to more effectively identify those @entity1 that will benefit from targeted therapies. Although many promising results have been derived from these studies there remains a lack of validated clinically applicable biomarkers available for translation into routine clinical use. This review will provide an overview of the recent proteomic research on upper @entity1820 protein biomarker identification and validation. The challenges faced in the development of validated, clinically acceptable and accurate protein biomarkers will also be discussed, along with possible areas of future progress. This article is protected by copyright. All rights reserved.
